SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)
This is a phase 3, multicentri, randomised, open label study. The purpose is to investigate the safety and efficacy of stereotactic body radiation therapy (SBRT) combined with transarterial chemoembolization (TACE) and lenvatinib (LEN) in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus.
Advanced Hepatocellular Carcinoma
DRUG: Lenvatinib|PROCEDURE: TACE|RADIATION: SBRT
Overall Survival (OS), OS is defined as the time from first treatment to death, regardless of disease recurrence., Up to 2 years
Progression-Free Survival (PFS), PFS is defined as the time from the first treatment to progression or death., Up to 2 years|Objective Response Rate (ORR), ORR is defined as the percentage of patients who have achieved complete response (CR) or partial response (PR), as measured by modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria., Up to 2 years|Disease Control Rate (DCR), DCR is defined as the percentage of patients who have achieved CR, PR or stable disease(SD), as measured by mRECIST criteria., Up to 2 years|Incidence of Adverse Events (AE), Incidence of AE is defined as the percentage of patients who suffer adverse events from the first treatment to last follow-up, assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0., Up to 2 years|Time to Progression （TTP）, TTP is defined as the time from the first treatment to progression., Up to 2 years
This is a phase 3, multicentri, randomised, open label study. The purpose is to investigate the safety and efficacy of stereotactic body radiation therapy (SBRT) combined with transarterial chemoembolization (TACE) and lenvatinib (LEN) in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus.